Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Summary Background The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy of FOLFIRI plus either cetuximab or bevacizumab according to the patients’ age and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2022-09, Vol.127 (5), p.836-843
Hauptverfasser: Fischer, Laura E., Stintzing, Sebastian, von Weikersthal, Ludwig Fischer, Modest, Dominik P., Decker, Thomas, Kiani, Alexander, Kaiser, Florian, Al-Batran, Salah-Eddin, Heintges, Tobias, Lerchenmüller, Christian, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Stauch, Martina, Scheithauer, Werner, Giessen-Jung, Clemens, Uhlig, Jens, Peuser, Bettina, Denzlinger, Claudio, Stahler, Arndt, Weiss, Lena, Heinrich, Kathrin, Held, Swantje, Jung, Andreas, Kirchner, Thomas, Heinemann, Volker
Format: Artikel
Sprache:eng
Schlagworte:
692/4028/67/1059/602
692/4028/67/1059/99
692/4028/67/1504/1885/1393
Bevacizumab
Biomedical and Life Sciences
Biomedicine
Cancer Research
Colorectal cancer
Colorectal carcinoma
Drug Resistance
Epidemiology
Metastases
Metastasis
Molecular Medicine
Monoclonal antibodies
Older people
Oncology
Patients
Survival
Targeted cancer therapy
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy of FOLFIRI plus either cetuximab or bevacizumab according to the patients’ age and sidedness of primary tumour. Methods The study endpoints overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) were compared between younger (
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-022-01854-y